Senator Abid Sher Ali calls on FDA DG to discuss development needs

FAISALABAD, Nov 03 (APP): Senator Chaudhry Abid Sher Ali called on Director General (DG) Faisalabad Development Authority (FDA), Muhammad Asif Chaudhry to discuss development needs of the city, public issues relating to FDA and effective and sustainable measures for their resolution.
PML-N leader Imran Sher Ali and party workers were also present on the occasion.
Welcoming Senator Chaudhry Abid Sher Ali, DG FDA Muhammad Asif Chaudhry briefed him about the ongoing activities of the authority, modern urban requirements, and future development needs.
He further informed him that extensive reform initiatives were underway to improve the overall performance of the FDA, enhance institutional capacity, and make public service delivery more efficient.
He said that the primary objective of these initiatives was to promote efficiency, transparency, merit, and accountability in official affairs.
Special emphasis was also being placed on expanding the use of modern technology and digital systems to ensure convenient, speedy and transparent service delivery to citizens.
During meeting, Senator Chaudhry Abid Sher Ali highlighted certain issues faced by the residents of Ahmad Nagar and stressed the need for their immediate resolution, along with providing maximum possible relief to the affected citizens.
Appreciating the overall performance of the FDA and implementation of modern institutional reforms, he observed that an effective administrative strategy and competent leadership played a vital role in improving institutional performance and making public service delivery more result-oriented.
On the occasion, DG FDA Muhammad Asif Chaudhry assured the senator that the issues faced by the residents of Ahmad Nagar would be examined in accordance with the prescribed rules and regulations and the available legal provisions to ensure appropriate and sustainable solutions.
He directed Director Estate Management-I, Junaid Hassan Manj, to examine the highlighted matters and identify appropriate solutions.
He further emphasized that the timely redressal of public complaints, transparent administrative procedures, and provision of improved facilities to citizens were among the top priorities of the FDA, and all relevant departments were being kept actively engaged to achieve these objectives.